Celecoxib and Colchicine Compatibility with Breastfeeding
Both celecoxib and colchicine are compatible with breastfeeding and can be continued safely while nursing.
Celecoxib During Breastfeeding
Celecoxib is safe to use during breastfeeding, with minimal infant exposure. According to the 2020 Association of Anaesthetists guideline, the relative dose that infants are exposed to via milk is very low, and breastfeeding may continue 1. This recommendation is reinforced by the 2025 EULAR guidelines, which do not list celecoxib among drugs to avoid during lactation 2.
Evidence Supporting Celecoxib Safety:
- Milk-to-plasma ratio: Studies demonstrate a median M/P ratio of 0.18 (range 0.15-0.26), indicating minimal transfer into breast milk 3
- Infant exposure: The relative infant dose averages only 0.23-0.30% of the weight-adjusted maternal dose 3, 4
- Clinical significance: This exposure level is far below the threshold of concern (typically <10% is considered safe)
- No adverse effects: Multiple studies found no untoward effects in breastfed infants exposed to celecoxib 4, 5
Colchicine During Breastfeeding
Colchicine is compatible with breastfeeding, though caution and infant monitoring are warranted. The FDA label states that colchicine is excreted into human milk, with exclusively breastfed infants receiving less than 10% of the maternal weight-adjusted dose 6. The 2025 EULAR guidelines explicitly support colchicine use in male patients trying to conceive and do not list it among drugs to avoid during lactation 2.
Evidence Supporting Colchicine Safety:
- Breast milk concentrations: Levels range from 1.9-8.6 ng/mL, similar to serum concentrations but representing minimal absolute amounts 7
- Clinical outcomes: A prospective study of 38 colchicine-exposed breastfed infants found no increase in adverse symptoms (3/38 vs 4/76 controls, p=0.68), no abnormal growth, and no increase in developmental delays 8
- Long-term safety: Follow-up data support continuation of breastfeeding in women treated with colchicine 8
Important Monitoring Considerations for Colchicine:
The FDA label advises caution because colchicine can affect gastrointestinal cell renewal and permeability 6. If you prescribe colchicine to a breastfeeding mother:
- Advise the mother to observe the infant for gastrointestinal symptoms (diarrhea, vomiting, poor feeding)
- Monitor for signs of bone marrow suppression if prolonged use (unusual bruising, pallor, increased infections)
- Consider timing doses immediately after breastfeeding to minimize infant exposure
- Discuss with the infant's pediatrician about monitoring for potential adverse effects
Clinical Pitfalls to Avoid:
Drug interactions with colchicine: The narrow therapeutic window means that interacting medications (macrolides, azole antifungals, certain statins) can increase toxicity risk 9. Review all maternal medications before prescribing.
Renal/hepatic impairment: Colchicine clearance is significantly reduced in organ dysfunction, increasing both maternal and potentially infant exposure 6. Dose adjustment may be necessary.
Don't confuse celecoxib with etoricoxib: The 2025 EULAR guidelines specifically list etoricoxib (not celecoxib) among NSAIDs to avoid during breastfeeding due to insufficient data 2.
Avoid unnecessary discontinuation: The 2020 anaesthesia guideline notes that ibuprofen and diclofenac are also safe NSAIDs during breastfeeding 1. If celecoxib is medically indicated, there's no need to switch medications solely for breastfeeding concerns.